Format

Send to

Choose Destination
Neurology. 2004 Sep 14;63(5):904-6.

Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.

Author information

1
Department of Neuro-Oncology, Erasmus MC, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.

Abstract

The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma. The genotype of the tumors was assessed with fluorescent in situ hybridization with locus specific probes for the region 1p36. Four of the 24 patients responded (17%). Fifty percent of patients were still free from progression at 6 months and 21% were free from progression at 12 months. Although a clear relation existed between loss of 1p and response to temozolomide chemotherapy, this relation was absent in salvage PCV chemotherapy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center